Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.
The journal of prevention of Alzheimer's disease
View this publicationMember
Kerpener Str. 62, 50931 Cologne
The main objective of Dr. Ramirez’s laboratory is the identification of the genetic and epigenetic architecture that influences the disease processes underlying cognitive disorders such as Alzheimer’s disease. A key focus of his research is identifying the molecular mechanisms at the intersection of ageing and Alzheimer’s disease that drive cognitive decline. His group combines (epi)genomics and proteomics to study cellular senescence, a key mechanism that triggers chronic inflammation through the senescence-associated secretory phenotype (SASP).
The journal of prevention of Alzheimer's disease
View this publicationNature aging
View this publicationFrontiers in neuroscience
View this publication